AGP Picks
View all

Insurance Press Releases: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Insurance Press Releases.

Press releases published on October 25, 2026

Azenta, Inc. Investor News: If You Have Suffered Losses in Azenta, Inc., You Are Encouraged to Contact The Rosen Law Firm About Your Rights
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Honeywell Aerospace Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HONA
Webull Corporation (BULL) Class Action Lawsuit: Investors Face December 7, 2026, Deadline - Kessler Topaz Meltzer & Check, LLP
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Coastal Financial Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - CCB
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Triller Group Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ILLR
XTIA EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds XTI Aerospace Investors of Securities Class Action Lawsuit Deadline on October 27, 2026
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Patients Undergoing Liver Resection for Colorectal Cancer …
ذكاء يتجلّى بوضوح: LUXEED تدشّن حضورها العالمي برؤية جديدة للفخامة ومتعة القيادة من خلال الذكاء
KECERDASAN, TERCERAHKAN: LUXEED Resmi Debut di Panggung Global, Mendefinisikan Ulang Kemewahan dan Kenikmatan Berkendara melalui Teknologi Cerdas
INTELLIGENCE, ENLIGHTENED: LUXEED เปิดตัวสู่ตลาดโลก…
Beyond Live Streaming: Tango Gives Back by Supporting Cancer Detection in Ukraine
Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
BioNTech und Bristol Myers Squibb präsentieren ermutigende Daten aus globaler Phase-2-Studie mit Pumitamig bei fortgeschrittenem nicht-kleinzelligem Lungenkrebs nach Progression der Erkrankung unter einer Immuntherapie und Chemotherapie
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
ThinkCareBelieve:  Week 92 of the 2nd Term of the Trump Administration

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Insurance Press Releases

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.